MONTREAL, Nov. 18, 2021 /CNW Telbec/ - Lumiera
Health Inc. (TSXV: NHP) (the "Company"
or "Lumiera "), a company specializing in the
development and commercialization of natural health products, is
pleased to announce that Louis Doyle
has been appointed to the Board of Directors of the Company
following the resignation of Nathalie
Nasseri as a director of the Company.
![Lumiera Health Inc. logo (CNW Group/Lumiera Health Inc.) Lumiera Health Inc. logo (CNW Group/Lumiera Health Inc.)](https://mma.prnewswire.com/media/1692461/Lumiera_Health_Inc__Lumiera_Health_Appoints_Louis_Doyle_to_Board.jpg)
Mr. Doyle has over 30 years of experience focused primarily on
capital markets and public companies. Mr. Doyle is currently
Executive Director and a director of Québec Bourse, the association
regrouping Québec based listed companies and other markets
stakeholders. Between October 1999
and December 2015 he was the
Vice-President, Montréal of TSX Venture Exchange. As such, he was
responsible for business development and listing activities in the
Province of Québec and Atlantic
Canada and responsible for managing the Montréal listings
team. During his tenure, he acted as chairman of TSX Venture
Listing Committee and was member of the Policy committee. Mr. Doyle
also led the nationwide TSX Venture Mentorship program and further
acted regularly as a speaker and advisor at conferences and
workshops. He has also held directorship roles with publicly traded
companies, the latest of which was Abitibi Royalties Inc.
The Board of Directors believes that Mr. Doyle will further
complement the Board's abilities as the Company moves forward. M.
Doyle will not only be a member of the Board, he will also be
leading the Audit Committee. "We are very excited to have Mr. Doyle
join our Board" said Carlos Ponce,
CEO of Lumiera. "His experience and strategic insight will no doubt
be of tremendous value as we execute our plan for growth."
The Board also thanks Mrs. Nasseri for her significant
contribution to set Lumiera up for accelerated growth and wishes
her well in her future endeavours. Mrs. Nasseri's decision to
resign from the Board of Directors came from a potential conflict
of interest and was not the result of any disagreement relating to
the Corporation's operations, policies or practices.
The Company's Board has granted an incentive stock options to
Mr. Doyle, entitling the purchase of an aggregate 300,000 common
shares at a per share price of $0.05
for a period of 10 years.
About Lumiera Health
Lumiera specializes in the development and commercialization of
consumer products for the natural health industry. The Company
sells herbal tonics and natural supplements through its Holizen
Laboratories division, with a diverse portfolio including a line of
innovative sleep aids. The Company is also developing and
commercializing a unique range of products acting on the
endocannabinoid system and offering novel solutions for the
treatment of acute and chronic pain. A pioneer in innovation of
plant-based health solutions, the Lumiera brand is rooted in the
core values of science, nature and compassion. Passionate about
making people feel better, we deliver trustworthy and
scientifically proven solutions that work with the body's own
systems.
For more information visit: www.lumiera.ca.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking information
Certain statements contained in this press release constitute
"forward-looking information" as such term is defined in applicable
Canadian securities legislation. The words "may", "would", "could",
"should", "potential", "will", "seek", "intend", "plan",
"anticipate", "believe", "estimate", "expect" and similar
expressions indicate such "forward-looking
information" as they relate to Lumiera. All statements other
than statements of historical fact may be forward-looking
information. Such statements reflect Lumiera' current views and
intentions with respect to future events, and current information
available to Lumiera, and are subject to certain risks,
uncertainties and assumptions. Such risks and uncertainties
include, among others, the risk factors included in Lumiera' annual
management's discussion and analysis for the year
ended November 30, 2020,
which is available under the issuer's SEDAR profile
at www.sedar.com. Material factors or assumptions
were applied in providing forward-looking information. Many factors
could cause the actual results, performance or achievements that
may be expressed or implied by such forward-looking information to
vary from those described herein should one or more of these risks
or uncertainties materialize. Should any factor affect Lumiera in
an unexpected manner, or should assumptions underlying the
forward-looking information prove incorrect, the actual results or
events may differ materially from the results or events predicted.
Any such forward-looking information is expressly qualified in its
entirety by this cautionary statement. Moreover, Lumiera does not
assume responsibility for the accuracy or completeness of such
forward-looking information. The forward-looking information
included in this press release is made as of the date of this press
release and Lumiera undertakes no obligation to publicly update or
revise any forward-looking information, other than as required by
applicable law.
SOURCE Lumiera Health Inc.